Colorectal Cancer | Specialty

Dr. Peeters on KRAS/NRAS Mutations in mCRC

February 6th 2014

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses an analysis of RAS mutations in the phase III study 20050181, which compared panitumumab plus FOLFIRI versus FOLFIRI for second-line treatment of mCRC

Robert McCormack Explains the CellSearch CTC Test

February 5th 2014

Robert McCormack, PhD, head, Technology Innovation, Janssen Diagnostics, LLC, explains the circulating tumor cell test CellSearch.

Cytoreductive Surgery and HIPEC for Peritoneal Carcinomatosis

February 5th 2014

The management of patients with malignant peritoneal surface disease (PSD) commonly known as "carcinomatosis" continues to evolve.

Examining the Role of Vitamin D in Colorectal Cancer Survival

January 27th 2014

Epidemiologic and scientific research indicates that diet and other lifestyle factors have a significant influence on the risk of developing colorectal cancer.

Dr. Bordonaro on First-Line Treatment Options for mCRC

January 24th 2014

Roberto Bordonaro, MD, discusses first-line treatment options for advanced colorectal cancer (CRC).

Dr. Fakih on RAS Mutations in Colon Cancer

January 22nd 2014

Marwan G. Fakih, MD, professor, director, Gastrointestinal Medical Oncology, City of Hope, discusses extended RAS mutations in colon cancer.

RAS Mutational Analyses in mCRC Trials Highlight Need to 'Think Beyond KRAS'

January 20th 2014

Studies presented at the 2014 GI Cancers Symposium emphasized the need for full RAS mutational analyses in the management of metastatic colorectal cancer prior to initiating treatment with anti-EGFR monoclonal antibodies.

Dr. John Marshall Provides Colorectal Cancer Updates

January 17th 2014

John L. Marshall, MD, from Georgetown University Hospital, on the recent advancements in colorectal cancer.

Neoadjuvant Capecitabine Considered a New Standard of Care in Rectal Cancer

January 14th 2014

Single-agent neoadjuvant capecitabine combined with radiation therapy demonstrated similar outcomes as previously established standards of care for patients with stage II or stage III rectal cancer.

Second-Line mCRC Data Further Support RAS Testing Before Panitumumab Use

January 14th 2014

An analysis of phase III, second-line data has shown that RAS mutations beyond KRAS exon 2 are negative predictive biomarkers for the EGFR-inhibitor panitumumab in metastatic colorectal cancer.

Dr. Fuchs on Aspirin for the Treatment of Colorectal Cancer

December 3rd 2013

Charles S. Fuchs, MD, MPH, director, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, discusses the use of aspirin for the prevention and treatment of colorectal cancer.

Improving Colorectal Cancer Screening Rates Among African Americans

November 13th 2013

Colorectal cancer is the third leading cause of cancer death among African Americans. The CRC mortality rate among African Americans is 29.8% compared with 19.5% among Caucasians.

Colonoscopy Screening at 10-Year Intervals May Prevent 40% of Colorectal Cancers

October 30th 2013

Forty percent of cases of colorectal cancer may be prevented if patients at average risk for the disease undergo a screening colonoscopy every 10 years

Dr. Ruff on the Timing of CRC Treatment With Aflibercept

October 28th 2013

Paul Ruff, MD, director of Medical Oncology at the University of Witwatersrand, Johannesburg, South Africa, discusses the decision regarding the timing of treatment with aflibercept for patients with colorectal cancer.

Side Effect Management With Corticosteroids

October 27th 2013

The Role of Patient Education in Side Effect Management

October 27th 2013

Managing BRAF Inhibitor Associated Skin Toxicity

October 27th 2013

The Nurse's Role in Managing Skin Toxicity

October 27th 2013

Managing mTOR Inhibitor Induced Adverse Events

October 27th 2013

Interdisciplinary Approach to Managing Skin Toxicities

October 27th 2013